Assessing the efficacy of treatment in disorders of the brain like Alzheimer’s disease, chronic pain, epilepsy, depression and anxiety is a lengthy and predominantly subjective process.
Due to the constraints of existing technology, the doctor can assess the efficacy of a treatment when it has already been on the way for several weeks or months, sometimes based solely on the patients’ feedback or subjective assessment of cognition, behaviour and activities of daily living (ADL). Objective assessment of pharmaceutical drugs for treatment of the central nervous system (CNS) has been possible only with indirect measurements of changes in blood flow or anatomy (fMRI, CT). But these indirect measurements are unable to detect the direct functional changes in the brain where CNS therapeutic drugs deploy their affect.
Functional changes to neuronal network induced by the treatment precede anatomical or blood flow changes. Therefore their detection and measurement is the quickest method for objective treatment efficacy assessment. DELPhI system is able to achieve this by measuring the treatment induced changes to the basal neuronal network state. Because the changes are observed and measured on the level of the brains’ primary activity, the effects of the treatment are seen almost instantly. Consequently the treatment can be objectively monitored and adapted to the patients’ individual response.